The role played by hepatitis C virus (HCV)-specific immune responses in the outcome of HCV infection is incompletely understood. Because HCV is believed to be noncytopathic, the immune response has been thought to play a key role in the hepatic damage and ensuing fibrosis that occurs during chronic infection. However, accumulating data from multiple laboratories have indicated that there is an association between enhanced HCV-specific T cell immunity and both recovery from acute infection [1] [2] [3] and antiviral therapyinduced viral clearance [4] [5] [6] [7] . These data suggest that
vigorous and broad-based HCV-specific T cell immunity is beneficial to the host and favors viral clearance.
The investigations described here were conducted in the context of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial, which is a controlled, randomized clinical trial of patients with chronic hepatitis C and advanced hepatic fibrosis (Ishak fibrosis score of у3) for whom interferon (IFN)-a therapy had previously failed [8] . We previously reported that the rate of sustained virologic response to re-treatment with pegylated IFN-a2a and ribavirin in the initial phase of the HALT-C Trial was low (18%) [9] and that immunologic and virologic measurements demonstrated a lack of association with the pretreatment clinical and histologic characteristics of this cohort [10] . In the present study, we simultaneously examined HCV-specific peripheral blood lymphoproliferative (LP) responses, HCV-specific intrahepatic cytotoxic T lymphocyte (CTL) responses, HCV E1 and E2 neutralizing antibody (NA) responses, and HCV E2 hypervariable region (HVR) 1 quasi-species (QS) diversity and complexity before the initiation of antiviral therapy in patients who completed at least 20 weeks of treatment. The goal of the study was to determine how baseline immune responses and viral variability might predict either on-treatment virologic response or subsequent treatment outcome in this group of patients with advanced hepatic fibrosis and prior nonresponse to IFN-a therapy. Finally, we sought to better understand the interactions between different components of the immune response and the virus itself.
PATIENTS, MATERIALS, AND METHODS

Patients.
The design of the HALT-C Trial has been described elsewhere [8] . Briefly, criteria for enrollment were chronic HCV infection with a detectable serum HCV RNA level, prior nonresponsiveness to IFN-a therapy (with or without ribavirin), and the presence of bridging fibrosis or cirrhosis in liver-biopsy samples obtained during the 12 months before enrollment. All liver-biopsy and peripheral blood samples were prospectively collected at 4 of 10 HALT-C clinical sites before the initiation of therapy; the 4 sites that participated did so on the basis of investigator interest. The institutional review boards of all involved institutions approved the study protocols, and written, informed consent was obtained from all study participants. The patients in the present analysis had usable results for any of the 4 substudies (the intrahepatic CTL, peripheral blood LP, NA, or QS substudies). Evaluation of serum HCV RNA levels, HCV genotype, and liver biopsies were performed as described elsewhere [9] . Patients were treated for 20 weeks with pegylated IFN-a2a (180 mg weekly; PEGASYS, Roche Pharmaceuticals) and ribavirin (1000-1200 mg daily, depending on body weight; COPEGUS, Roche Pharmaceuticals) in 2 divided doses. At the week 20 (W20) time point, serum HCV RNA levels were tested in duplicate using the qualitative Roche COBAS Amplicor assay (version 2.0; Roche Molecular Systems). Patients with undetectable serum HCV RNA levels at W20 (virologic responders [VRs] ) continued the combination therapy for 28 additional weeks (for a total of 48 weeks) and then were followed for 24 weeks; those with undetectable serum HCV RNA levels at the week 72 (W72) time point were considered to be sustained VRs (SVRs; figure 1). Patients with detectable serum HCV RNA levels at W20 entered the randomized phase of the HALT-C Trial and were considered to be W20 non-VRs as well as W72 non-SVRs. Finally, patients with undetectable serum HCV RNA levels at W20 but in whom serum HCV RNA reappeared at any time point after W20 were considered to be breakthrough/ relapse patients and were included in the non-SVR group. Patients who had missing HCV RNA data at W20 or W72 were considered to be non-VRs (intention-to-treat analysis).
LP, CTL, NA, and QS assays. Lymphoproliferative responses to superoxide dismutase (SOD)-recombinant HCV genotype 1a protein antigens SOD-c22 (HCV aa 2-120), SODc100 (HCV aa 1569-1931), SOD-NS5 (HCV aa 2054-2995), Escherichia coli-derived SOD-c33c (HCV aa 1192-1457) and recombinant human SOD (all gifts from M. Houghton, Chiron) were measured in quadruplicate wells using [ 3 H]-thymidine incorporation assays with freshly isolated peripheral blood mononuclear cells (PBMCs), as described elsewhere [10, 11] . T cell lines were derived from fresh liver-biopsy samples (length, ∼0.5 cm) and tested in triplicate wells for cytolysis of autologous 51 Cr-labeled B lymphoblastoid cell lines (BLCLs) infected with recombinant vaccinia viruses expressing regions spanning the entire HCV genotype 1a polyprotein-aa 1-339 (C-E1; vv9A), aa 347-906 (E2-NS2; vv1H), and aa 827-3011 (NS2-NS5; vv827), or b-galactosidase as a negative control, as described elsewhere [10, 12, 13] . HCV chimeric envelope glycoprotein (E1-G or E2-G; genotype 1a)/vesicular stomatitis virus (VSVts045; temperature-sensitive mutant of VSV) pseudotype viruses (∼100 pfu) were incubated with serial dilutions of heat-inactivated test sera, and plaques on baby hamster kidney cell monolayers were counted to assess NA activity, as described elsewhere [10, 14, 15] .
HCV QS diversity and complexity were evaluated by clonal frequency analysis of the E2 HVR1, as described elsewhere [10, 16] . For each patient, 20 individual QS clones from frozen baseline serum samples were analyzed.
LP assays were scored as positive when the stimulation index (SI) value for any HCV antigen was 14. The SI was defined as the ratio of the mean test antigen cpm/mean control cpm. CTL assays were scored as positive when the percentage of specific lysis of BLCLs infected with HCV-vaccinia recombinant viruses was 110% above the percentage of specific lysis of the control target cells at 1 or more effector-to-target cell ratios. NA assays were scored as positive when у50% neutralization against either E1-or E2-pseudotyped viruses was detected. These cutoffs Trial. All patient samples tested by the lymphoproliferative, cytotoxic T lymphocyte, neutralizing antibody, and quasi-species assays were obtained at baseline, before the initiation of pegylated interferon (IFN)-a2a (PEGASYS; Roche Pharmaceuticals) and ribavirin combination therapy. On-treatment virologic response was assessed after 20 weeks of therapy, and patients were categorized as week 20 (W20) virologic responders (VRs) or non-VRs on the basis of the results of serum hepatitis C virus (HCV) RNA testing using the qualitative Roche COBAS Amplicor assay (version 2.0). The W20 VRs continued the combination therapy for 28 additional weeks (for a total of 48 weeks) and then were followed for 24 weeks. Whether serum HCV RNA levels were detectable at week 72 (W72) determined the categorization of the patients as sustained virologic responders (SVRs) or non-SVRs. were selected before data analysis and were based on previous data, from our own laboratories and others, regarding the sensitivity and specificity of these assays, and they were clearly different from those for normal controls [7, 11-15, 17, 18] . Participating laboratories were blinded to treatment outcome. 
RESULTS
Characteristics of the study population and baseline immune responses.
Of the 367 patients analyzed in the present study who had treatment outcomes available, not all of them had samples tested for each of the substudies. Sample size limitations for the LP ( ), CTL ( ), and NA substudies n p 338 n p 210 ( ) have been described elsewhere [10] . QS analysis n p 244 was limited to HCV genotype 1-infected patients ( ). n p 103 Seventy-one patients had results for all 4 substudies. Demographic and other data describing all of the patients in this cohort are shown in table 1. The major difference between the overall cohort and the substudy cohorts was a somewhat lower prevalence of cirrhosis in the patients in the CTL substudy, which probably resulted from the greater difficulty in obtaining fresh liver tissue from those with cirrhosis for analysis [10] .
We also previously reported details on the limited specificity, magnitude, and breadth of immune responses observed in the overall cohort to the genotype 1a antigens used [10] . Positive CTL responses were more frequent in patients with nongenotype 1 infection than they were in patients with genotype 1 infection (30% vs. 20%; , Fisher's exact test), but this P p .31 difference was significant only in the case of CTL responses to C-E1 (vv9A) (20% vs. 7%; , Fisher's exact test). Ge-P p .047 notype did not appear to influence the frequency of positive LP or NA assay results (data not shown). All analyses were also performed including only those patients with HCV genotype 1 infection; the results obtained were not significantly different from those obtained in the analyses of the entire cohort. Figure 1 illustrates the study design. In the overall study cohort, 35% (127/367) achieved a virologic response at W20, as defined by an undetectable serum HCV RNA level at that time point (table 1) . Nineteen percent (70/367) became SVRs (undetectable serum HCV RNA level at W72). Treatment-response rates were not significantly different among the substudy populations and were similar to those observed in the HALT-C cohort ( ) [9] . n p 604 Similarity of the frequencies of LP, CTL, and NA responses at baseline in W20 VRs and non-VRs. To investigate the association between baseline immune response and on-treatment virologic response, patients were categorized as either W20 VRs or non-VRs, depending on the absence or presence of detectable serum HCV RNA after 20 weeks of pegylated IFN-a2a and ribavirin combination therapy. The percentage of patients with positive LP, CTL, or NA assay results at baseline was not different between W20 VRs and non-VRs, as is shown in figure 2A ( , , and , respectively; P p .59 P p 1.00 P p .20 Fisher's exact test). Patients who had missing serum HCV RNA data at W20 ( ) or W72 ( ) were classified as nonn p 25 n p 10 VRs. Removal of these patients from the analyses did not change any of the results (data not shown).
More frequent detection of LP and NA responses at baseline in non-SVRs than in SVRs. To determine whether baseline immune responses to HCV antigens might predict subsequent treatment-induced viral clearance, patients were categorized according to their virologic status at W72, after 48 weeks of pegylated IFN-a2a and ribavirin combination therapy and 24 weeks of follow-up. For this analysis, all patients with detectable serum HCV RNA levels at W20 as well as W72 were considered to be non-SVRs. The percentage of patients with positive LP, CTL, or NA assay results at baseline among the SVRs and the non-SVRs is shown in figure 2B . ). When patients with positive LP and NA assay results at baseline were compared with those with negative LP and NA assay results at baseline, it was found that no SVRs had positive results for both assays ( , Fisher's ex-P p .02 act test; NPV, 100%). These findings indicate that the presence of an HCV-specific immune response at baseline-whether determined by the NA assay alone, 1 or more of the assays, or both the NA and LP assays together-was associated with subsequent virologic nonresponse to antiviral therapy.
Because prior ribavirin therapy was a strong predictor of subsequent virologic nonresponse after pegylated IFN-a2a and ribavirin combination therapy in the overall HALT-C cohort [9] , the possibilities that prior ribavirin therapy (1) may have affected the LP and NA assay results at baseline and (2) may have selected for different populations of patients were considered. When the subset of patients without prior ribavirin therapy was examined ( ), the results were similar to n p 67 those for the overall cohort. Specifically, non-SVRs were more likely to have positive NA assay results at baseline than were SVRs ( , Fisher's exact test; data not shown). Non-SVRs P p .04 were also more likely to have positive LP assay results at baseline (31%) than were SVRs (17%), although the association was not statistically significant ( , Fisher's exact test). There-P p .20 fore, prior ribavirin therapy did not appear to significantly affect the relationship between baseline LP or NA responses and subsequent virologic response. The median interval from baseline immunologic testing and receipt of the last dose of ribavirin as part of the prior therapy was 25 months (range, 5-62 months).
Effect of the presence of cirrhosis on the association between baseline LP responses and subsequent virologic response to therapy. Given our previous finding in this cohort of a possible association between the presence of cirrhosis and a decreased frequency of HCV-specific LP responses [10] , we evaluated whether the presence of cirrhosis could affect the association between baseline LP responses and subsequent virologic response to therapy. When the presence of cirrhosis was controlled for, the association between a positive LP assay result at baseline and becoming an SVR was statistically significant ( , Cochran-Mantel-Haenszel test). Moreover, P p .04 when patients with cirrhosis (Ishak fibrosis score of 5 or 6) were excluded from the analysis, the association between a positive LP assay result at baseline and becoming a non-SVR was stronger ( , Fisher's exact test; OR, 0.38 [95% CI, P p .02 0.17-0.86]) (table 2). In the 104 patients with cirrhosis, however, the frequency of positive LP assay results at baseline was low (17/104 [16%]), and a positive result did not predict subsequent virologic nonresponse to therapy ( , Fisher's ex-P p .67 act test). Similar analyses did not reveal a significant influence of liver histology on the relationship between NA or CTL assay results and treatment outcome (data not shown). Furthermore, PBMC viability, which could have affected the results, was similar among the groups analyzed; did not vary with the degree of fibrosis, virologic response, or virologic nonresponse; and did not differ between patients with a positive LP assay result at baseline and those with a negative result (data not shown).
Confirmation, by multivariate logistic regression analysis, of the correlation between baseline immune responses and subsequent virologic response.
Apart from the presence of cirrhosis and prior ribavirin therapy, other important factors known to affect the virologic response to antiviral therapy are serum HCV RNA level, HCV genotype, and the amount of Table 2 . Association between a positive lymphoproliferative (LP) assay result at baseline and the inability to achieve a sustained virological response in patients with hepatic fibrosis but not cirrhosis. Increased baseline HCV QS diversity in non-VRs. Baseline HCV QS diversity (degree of nucleotide heterogeneity) and complexity (number of unique variants) were examined in 83 W20 non-VRs and 20 W20 VRs (8 of whom became SVRs) (figure 3A). For consideration of genetic diversity, a value of 1.0 denotes homogeneity; thus, decreasing values correlate with increasing heterogeneity at the nucleotide level [19, 20] . Both QS diversity and complexity were significantly higher at baseline in those who became W20 non-VRs than they were in those who became W20 VRs ( and , respectively; Wil-P p .04 P p .03 coxon rank sum test). Baseline QS diversity was also increased in non-SVRs, compared with that in SVRs ( , Wilcoxon P p .01 rank sum test) ( figure 3B, left panel) . Although the median QS complexity was increased in non-SVRs, compared with that in SVRs, only a statistical trend for this association was found ( , Wilcoxon rank sum test) (figure 3B, right panel). P p .09 When patients were categorized as W20 non-VRs, breakthrough/relapse patients, and SVRs, a stepwise decrement in QS diversity and complexity was found (for diversity, P p ; for complexity, ; Spearman's correlation coeffi-.02 P p .02 cient) ( figure 3C ). No association between serum HCV RNA levels and QS diversity or complexity was found ( and P p .31 , respectively; Spearman's correlation coefficient). Fi-P p .56 nally, no direct associations could be established between results for the LP, CTL, or NA assays and the HCV QS analysis, even when results for individual antigens were considered.
DISCUSSION
In our cohort of 367 patients tested for HCV-specific immune responses before the initiation of therapy, we found a surprising association between the presence of baseline LP and NA responses and subsequent failure to achieve viral clearance with state-of-the-art antiviral therapy. The unique features of the present study included the large number of samples tested for multiple aspects of the immune response, the specialized cohort of patients with advanced hepatic fibrosis and prior nonresponse to IFN-a therapy, and our focus on the relationship between baseline immune responses and QS variability before the initiation of therapy and subsequent treatment outcome. Multivariate logistic regression analysis that controlled for the presence of cirrhosis, prior ribavirin therapy, genotype 1 infection, log serum HCV RNA level, and receipt of 180% of the prescribed pegylated IFN-a2a and ribavirin revealed that both a positive LP assay result at baseline and 1 or more positive immunologic assay results at baseline predicted subsequent non-SVR status at W72. This is the first report to describe HCV-specific immune responses before the initiation of therapy and relate them to treatment outcome in such a large group of prior non-VRs with advanced hepatic fibrosis.
Earlier studies have described an association between increased QS variability and nonresponse to therapy, although most [19, 21, 22] , but not all [23] , studied significantly fewer patients. We similarly demonstrated increased QS variation at baseline in patients who proceeded to virologic nonresponse at both W20 and W72, although ours is the first report of such a correlation in prior non-VRs with advanced hepatic fibrosis. Moreover, the present study found both increased QS variability and immune responses to be associated with subsequent virologic nonresponse, which is consistent with the notion that immune responses drive QS variation in vivo [24, 25] . However, we were not able to identify direct relationships between LP, CTL, or NA assay results and QS assay results. Our inability to detect these relationships could have resulted from a number of obstacles, such as the relatively small number of overlapping patients analyzed in the QS and immunologic assays, the nature of the cohort studied (all prior non-VRs with advanced hepatic fibrosis), and the fact that heterologous (rather than patient-specific) antigens were used in the immunologic assays. In addition, the LP assay did not specifically assess responses to the HCV E2 HVR1, which was assessed in the QS assay. Nevertheless, the associations of both increased baseline QS variability and increased baseline LP and NA responses with virological nonresponse lead us to hypothesize that T and B cell responses to HCV may have been sufficient to drive QS diversification but may not have been sufficient to predispose patients to virologic clearance. The parameters by which these immune responses are ineffective or counteractive with regard to viral eradication have yet to be defined. The baseline immune responses present in our eventual non-VR population were clearly inadequate-in terms of magnitude, breadth, and/or specificity (as detailed in Rothman et al. [10] )-for the purpose of eradicating HCV. Moreover, the immune responses detected were associated with subsequent nonresponse to antiviral therapy. This finding may appear to conflict with earlier data demonstrating a relationship between enhanced HCV-specific CD4 + T cell proliferative responses and subsequent virologic clearance [4] [5] [6] [7] . However, these other studies were performed in treatment-naive cohorts and focused on the development of T cell responses during and after therapy. By contrast, our cohort had longstanding advanced hepatic fibrosis, a history of prior nonresponse to IFN-a therapy, and was studied before the initiation of therapy. It is notable that African Americans, another treatment-resistant population, have recently been shown to more commonly exhibit HCV-specific CD4 + T cell proliferative responses than are Caucasian Americans [26] , further supporting the notion that pretreatment immune responses may be predictive of nonresponse to therapy in certain patient cohorts.
The question remains, however, as to why some patients with baseline immune responses were unable to convert them to ones that lead to viral clearance. Several potential hypotheses could explain our results. The persistent activity of immunoregulatory T cells in HCV-infected patients that serves to downregulate the immune response during the chronically infected state [27, 28] could prevent the generation of an appropriate immune response. Other potential mechanisms include host factors (such as cytokine polymorphisms) [29, 30] , the absence of an adequate T cell repertoire resulting from immune exhaustion [31] , and the phenomenon of "original antigenic sin" [32] , wherein the immune responses originally elicited by specific epitopes remain dominant, despite the evolution of variant viral epitopes. Future detailed studies will be required to determine which of these mechanisms is operant. Given the treatment-resistant advanced-disease state of our cohort, the HCV-specific immune responses we detected were, at best, ineffective-and, at worst, they served to impede the development of other, effective immune responses after re-treatment.
In conclusion, we found positive baseline HCV-specific immune responses and increased QS variability to be associated with a subsequent lack of sustained virologic response in a large cohort of patients with advanced hepatic fibrosis and prior nonresponse to IFN-a therapy, indicating an association between HCV-specific immune reactivity and a pretreatment state that is resistant to successful pegylated IFN-a2a and ribavirin combination therapy. Earlier findings from our group [10] and from others [33] have suggested that active intrahepatic HCVspecific CTL responses may be responsible for ongoing liver damage and may play a role in the progression of liver disease. Together, these data suggest that, in certain situations, the presence of an immune response may not necessarily benefit the host. Clearly, the role played by the immune response in the pathogenesis of hepatitis C disease is complex, and the difference between a beneficial and deleterious immune response will need to be carefully dissected as we consider the use of immune-enhancing or -modifying therapies in the future treatment of chronic hepatitis C. Baseline HCV QS diversity and complexity were analyzed by clonal frequency analysis after genotype 1-infected patients were categorized as virologic responders (VRs) or non-VRs at week 20 (W20; A) and as sustained VRs (SVRs) or non-SVRs at week 72 (W72; B). Panel C shows patients categorized as W20 NRs, breakthrough/relapse patients (BT/Rs), and SVRs. For consideration of genetic diversity, a value of 1.0 denotes homogeneity; thus, decreasing values correlate with increasing heterogeneity at the nucleotide level. Complexity shows the no. of unique variants. The columns indicate the range of values obtained between the 25th and 75th percentiles for diversity and complexity; the error bars indicate the lowest and highest nonoutlier values in each data set; the lines contained within the columns indicate the median value in each data set; and the circles indicate outliers that were 11.5 times the interquartile range from the median. Genetic diversity and complexity were compared between the patients with virologic response and those with nonresponse by use of the Wilcoxon rank sum test, whereas trends were tested by use of Spearman's correlation coefficient; P values are shown for each comparison. The total no. of patients in each group is shown in parentheses below the corresponding bar graph. 
